Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cebon

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
American Journal of Clinical Oncology|June 17, 1998
Dose escalation study of carboplatin and cyclophosphamide with filgrastim support: a phase I studyG C Toner, M Green, J F Bishop, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumoursP L R Mitchell, R Basser, M Chipman, et al.
Critical Care Medicine|August 2, 2000
Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: relation to disease severity, multiple organ dysfunction, and mortalityJ J Presneill, P M Waring, J E Layton, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 1994
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathologyE Stanley, G J Lieschke, D Grail, et al.
Behring Institute Mitteilungen|August 1, 1988
Clinical studies with granulocyte colony stimulating factor (G-CSF) in patients receiving cytotoxic chemotherapyG Morstyn, L Campbell, U Dührsen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 22, 1999
An HLA-A2 polyepitope vaccine for melanoma immunotherapyL Mateo, J Gardner, Q Chen, et al.
Bone Marrow Transplantation|July 1, 1994
Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignanciesW P Sheridan, C G Begley, L B To, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1995
Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cellsR L Basser, L B To, C G Begley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2000
Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancerR L Basser, C Underhill, I Davis, et al.
Blood|November 14, 1997
Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humansC G Begley, R Basser, R Mansfield, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
American Journal of Clinical Oncology|June 17, 1998
Dose escalation study of carboplatin and cyclophosphamide with filgrastim support: a phase I studyG C Toner, M Green, J F Bishop, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumoursP L R Mitchell, R Basser, M Chipman, et al.
Critical Care Medicine|August 2, 2000
Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: relation to disease severity, multiple organ dysfunction, and mortalityJ J Presneill, P M Waring, J E Layton, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 1994
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathologyE Stanley, G J Lieschke, D Grail, et al.
Behring Institute Mitteilungen|August 1, 1988
Clinical studies with granulocyte colony stimulating factor (G-CSF) in patients receiving cytotoxic chemotherapyG Morstyn, L Campbell, U Dührsen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 22, 1999
An HLA-A2 polyepitope vaccine for melanoma immunotherapyL Mateo, J Gardner, Q Chen, et al.
Bone Marrow Transplantation|July 1, 1994
Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignanciesW P Sheridan, C G Begley, L B To, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1995
Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cellsR L Basser, L B To, C G Begley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2000
Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancerR L Basser, C Underhill, I Davis, et al.
Blood|November 14, 1997
Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humansC G Begley, R Basser, R Mansfield, et al.
Pageof 7